National Tunisian Registry of Hypertension (NATURE-HTN)

March 31, 2022 updated by: Dacima Consulting

The Tunisian Society of Cardiology and Cardiovascular Surgery (STCCCV) proposes to coordinate a national, observational, cross-sectional and multicenter survey carried out during one month. The main objective of the survey is to describe the blood pressure and cardiovascular risk profile of the hypertensive patient in Tunisia.

This survey will allow us to have a generalized and updated view of the tunisian hypertensive patient in order to optimize treatment and to know the degree of adherence of practitioners to international recommendations in the care of the hypertension in Tunisia.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

25000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tunis, Tunisia, 1053
        • The Tunisian Society of Cardiology and CardioVascular Surgery

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 95 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients presenting in consultation of cardiology, general medicine / family medicine, internal medicine and nephrology will be recruited in the survey.

Description

Inclusion Criteria:

Age ≥ 18 years Informed consent, read and signed

Exclusion Criteria:

Consent not obtained

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Pressure Level
Time Frame: At inclusion
Mean of Systolic and Diastolic Blood Pressure in mmHg
At inclusion
Cardiovascular Risk Profile
Time Frame: At inclusion
Percentages & Frequencies of cardiovascular risk factors
At inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Leila ABID, MD, The Tunisian Society of Cardiology and CardioVascular Surgery

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 15, 2019

Primary Completion (ACTUAL)

May 15, 2019

Study Completion (ACTUAL)

May 15, 2019

Study Registration Dates

First Submitted

July 4, 2019

First Submitted That Met QC Criteria

July 6, 2019

First Posted (ACTUAL)

July 9, 2019

Study Record Updates

Last Update Posted (ACTUAL)

April 8, 2022

Last Update Submitted That Met QC Criteria

March 31, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DAC-006-NATUREHTN

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe